ArticleFrontiers in oncology2026

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study.

Zhong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.